@merz @failedLyndonLaRouchite @jgordon @DeanBaker13 no one argues for erasing the institutional history of pharma and restarting from some blank slate. we argue for changing the financing model under which those competencies get deployed. that does mean, going forward, different, likely smaller, flows of money to the industry. it does not mean burning anything down. (big pharma itself has done a lot of that to itself recently.)